TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27029390

Group type: EXPERIMENTAL
Intervention: Treatment for chronic progressive diseases (specific intervention details not available)
Number of subjects: 0
Study: 25545540

Group type: EXPERIMENTAL
Intervention: Esmolol (100 μg/kg per min for 10 mins, then 50 μg/kg per min for 50 mins)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tecadenoson (75 μg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tecadenoson (300 μg)
Number of subjects: 14
Study: 22562973

Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (ADA+MTX)
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Methotrexate monotherapy (PBO+MTX)
Number of subjects: 1032
Study: 22219096

Group type: EXPERIMENTAL
Intervention: BMSC transplantation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 60
Study: 18446847

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 80
Study: 16946216

Group type: EXPERIMENTAL
Intervention: Orange juice fortified with calcium
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dairy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study: 12971145

Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Number of subjects: 106

Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 106
Study: 10601674

Group type: EXPERIMENTAL
Intervention: Fear, induced by exposure to three brief shocks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anxiety, elicited by the threat of shock
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral, with no intervention
Number of subjects: 60
Study: 9135961

Group type: EXPERIMENTAL
Intervention: Trans monounsaturated fatty acid (TMUFA) diet
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Saturated fat (SAT) diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cis monounsaturated fatty acid (CMUFA) diet
Number of subjects: 16
Study: 8212369

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 3096035

Group type: EXPERIMENTAL
Intervention: Terbutaline (T)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Terbutaline (T) infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Terbutaline (T) with propranolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline with propranolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Terbutaline (T) and Saline
Number of subjects: 15
Study: 29898844

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4600

Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 4600

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4600
Study: 26586786

Group type: EXPERIMENTAL
Intervention: MTP-131 infused at a rate of 0.05 mg/kg/h for 1 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTP-131
Number of subjects: 0
Study: 24145543

Group type: EXPERIMENTAL
Intervention: Ganciclovir at 5 mg/kg body weight intravenously
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ganciclovir dose of 2.5 mg/kg once daily
Number of subjects: 9
Study: 22001666

Group type: EXPERIMENTAL
Intervention: Music intervention (at least 2 daily sessions of music listening between D0 and D10, continued at home until D60)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard treatment only (control group)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 87
Study: 19846597

Group type: EXPERIMENTAL
Intervention: Thyroid hemiagenesis (THA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (subjects with fully developed thyroid gland)
Number of subjects: 40
Study: 18763685

Group type: EXPERIMENTAL
Intervention: EMLA cream (2.5% lidocaine/2.5% prilocaine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oraqix thermosetting gel (2.5% lidocaine/2.5% prilocaine)
Number of subjects: 40
Study: 16053244

Group type: EXPERIMENTAL
Intervention: Protein source tryptophan (deoiled gourd seed) with carbohydrate
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pharmaceutical grade tryptophan with carbohydrate
Number of subjects: 57

Group type: COMPARATOR
Intervention: Carbohydrate alone
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Protein source tryptophan with carbohydrate
Number of subjects: 57
Study: 14748645

Group type: EXPERIMENTAL
Intervention: High-frequency words
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-frequency words
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-density words
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-density words
Number of subjects: 8
Study: 9915370

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis set at neutral with a flat sole line
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Standing-up motion restoration
Number of subjects: 1
Study: 8534467

Group type: EXPERIMENTAL
Intervention: Cancellation of elective surgery due to URI
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Experience of anesthesiologists
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Factors influencing cancellation decisions
Number of subjects: 212
Study: 2139413

Group type: EXPERIMENTAL
Intervention: synthetic ANF‐(99‐126) 50 micrograms bolus followed by 0.025 micrograms.kg‐1.min‐1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: sodium nitroprusside (SNP) 0.35 micrograms.kg‐1. min‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: vehicle 0.9% NaCl40 ml and 20% albumin 5 ml
Number of subjects: 10
Study: 6992833

Group type: EXPERIMENTAL
Intervention: Ro 10-9359 (100 mg daily initially, maintenance dose 50 mg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 30872600

Group type: EXPERIMENTAL
Intervention: Computed Tomography Texture Analysis (CTTA) combined with heterogeneity and radiomic features
Number of subjects: 253
Study: 27681710

Group type: EXPERIMENTAL
Intervention: Experimental training groups for early specialisation path
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Experimental training groups for late specialisation path
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-structured path
Number of subjects: 76
Study: 27260011

Group type: EXPERIMENTAL
Intervention: Personalized lifestyle advice plus tandem skydive
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Personalized lifestyle advice only
Number of subjects: 132

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Non-anhedonic control group
Number of subjects: 132
Study: 24806030

Group type: EXPERIMENTAL
Intervention: Acarbose/metformin 50/500 mg FDC (test)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acarbose 50 mg and metformin 500 mg as loose combination (reference)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acarbose/metformin FDC and loose combination
Number of subjects: 40
Study: 22504653

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 0
Study: 19513933

Group type: EXPERIMENTAL
Intervention: Moderate level of transference interpretations
Number of subjects: 100

Group type: COMPARATOR
Intervention: No transference interpretations
Number of subjects: 100
Study: 17205427

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study: 16344839

Group type: EXPERIMENTAL
Intervention: MAS XR 20‐60 mg/day
Number of subjects: 223
Study: 12170853

Group type: EXPERIMENTAL
Intervention: ITI implant system
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Steri-Oss implant system
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Southern implant system
Number of subjects: 72

Group type: COMPARATOR
Intervention: Southern group
Number of subjects: 72

Group type: COMPARATOR
Intervention: ITI group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Steri-Oss group
Number of subjects: 72
Study: 10221686

Group type: COMPARATOR
Intervention: 100 IU FSH
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 200 IU FSH
Number of subjects: 199
Study: 8552232

Group type: EXPERIMENTAL
Intervention: Baclofen (GABAB receptor agonist) administered pre-operatively with morphine (mu-opioid analgesic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baclofen (GABAB receptor agonist) administered with pentazocine (kappa-opioid analgesic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentazocine (kappa-opioid analgesic)
Number of subjects: 0
Study: 2364407

Group type: EXPERIMENTAL
Intervention: Toothpaste with 1,000 ppm fluoride (NaF or Na2PO3F)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dicalcium phosphate dihydrate toothpaste
Number of subjects: 8

Group type: COMPARATOR
Intervention: Other toothpastes (chalk, silica or alumina with sodium monofluorophosphate, silica with sodium fluoride)
Number of subjects: 8
Study: 6107097

Group type: EXPERIMENTAL
Intervention: Org NC 45
Number of subjects: 64

Group type: COMPARATOR
Intervention: pancuronium
Number of subjects: 64

Group type: COMPARATOR
Intervention: alcuronium
Number of subjects: 64

Group type: COMPARATOR
Intervention: tubocurarine
Number of subjects: 64
Study: 30377187

Group type: EXPERIMENTAL
Intervention: Online-DPP
Number of subjects: 378

Group type: COMPARATOR
Intervention: VA-DPP
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Both DPPs
Number of subjects: 378
Study: 27552802

Group type: EXPERIMENTAL
Intervention: Educational session focusing on the importance of adherence to medication (30 minutes)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group (no educational session)
Number of subjects: 446
Study: 24893602

Group type: EXPERIMENTAL
Intervention: Real-time assessment of predictors (motivation for quitting, smoking expectancies, quit self-efficacy, smoking urges, negative affect, positive affect, restlessness, hostility, and stress) during the 6 days prior to a scheduled quit attempt.
Number of subjects: 57
Study: 22829691

Group type: EXPERIMENTAL
Intervention: Low-dose etanercept (25 mg/week)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard-dose etanercept (50 mg/week)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (Low-dose and Standard-dose etanercept)
Number of subjects: 70
Study: 20833514

Group type: COMPARATOR
Intervention: Olanzapine (mean dose 10.9 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ziprasidone (mean dose 88.9 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Olanzapine to Ziprasidone switch (mean dose 136 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ziprasidone to Olanzapine switch (mean dose 16 mg)
Number of subjects: 49
Study: 18655723

Group type: EXPERIMENTAL
Intervention: Pedometer-based walking programme combined with physical activity consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control for 12 weeks (followed by minimal pedometer-based intervention)
Number of subjects: 0
Study: 15905753

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 16
Study: 12629228

Group type: EXPERIMENTAL
Intervention: [18F]FCWAY V PET in patients with temporal lobe epilepsy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: [18F]FCWAY V in patients with temporal lobe epilepsy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: [18F]FCWAY V asymmetry index (AI) in ILT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: [18F]FCWAY V AI in IMT
Number of subjects: 22
Study: 11202292

Group type: EXPERIMENTAL
Intervention: Open abdomen method (OAM)
Number of subjects: 50
Study: 8822756

Group type: EXPERIMENTAL
Intervention: Smoking (two non-filtered cigarettes for 4 minutes)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (not smoking)
Number of subjects: 18
Study: 1582456

Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-osteosynthesis
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 6734209

Group type: EXPERIMENTAL
Intervention: TCu 380Ag
Number of subjects: 2762

Group type: EXPERIMENTAL
Intervention: TCu 220C
Number of subjects: 2762

Group type: COMPARATOR
Intervention: Mahua double ring
Number of subjects: 2762

Group type: COMPARATOR
Intervention: Mahua device
Number of subjects: 2762
Study: 30448014

Group type: EXPERIMENTAL
Intervention: Prone position (7 cmH2O CPAP for 1 hour)
Number of subjects: 14
Study: 29300423

Group type: EXPERIMENTAL
Intervention: RE plus dairy protein and micronutrient supplementation
Number of subjects: 82

Group type: COMPARATOR
Intervention: RE only
Number of subjects: 82
Study: 26427866

Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine (LE; 1:80,000)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lidocaine with clonidine (LC; 15 mcg/ml)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine (LE; 1:80,000) and Lidocaine with clonidine (LC; 15 mcg/ml)
Number of subjects: 72
Study: 1467204

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 0
Study: 22083026

Group type: EXPERIMENTAL
Intervention: Attention training toward threat
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Attention training away from threat
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Attention training
Number of subjects: 49
Study: 20412218

Group type: EXPERIMENTAL
Intervention: Dry wash shampooing (DW)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Regular wash shampooing
Number of subjects: 67
Study: 18238740

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) therapy
Number of subjects: 0
Study: 15841875

Group type: EXPERIMENTAL
Intervention: Internalization measure
Number of subjects: 549

Group type: COMPARATOR
Intervention: Other affect-related measures
Number of subjects: 549

Group type: COMPARATOR
Intervention: History of major depression
Number of subjects: 549
Study: 12427351

Group type: EXPERIMENTAL
Intervention: Worksite stress management intervention focused on enhancing positive coping styles and decreasing negative coping styles.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group with delayed intervention.
Number of subjects: 95
Study: 10769603

Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus (300 mg capsules, 3 capsules thrice daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (antacid powder in similar capsule form)
Number of subjects: 57
Study: 7562263

Group type: EXPERIMENTAL
Intervention: mapping-enhanced counseling
Number of subjects: 93

Group type: COMPARATOR
Intervention: standard counseling
Number of subjects: 93
Study: 1777551

Group type: EXPERIMENTAL
Intervention: Azapropazone with glucose and sodium citrate (1:1:1 by weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azapropazone alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azapropazone with glucose and sodium citrate
Number of subjects: 0
Study: 6846115

Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acebutolol (both doses)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 25
Study: 29505385

Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Waitlist (control)
Number of subjects: 68
Study: 28252471

Group type: EXPERIMENTAL
Intervention: Balance training with a dynamometric platform
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group training without a dynamometric platform
Number of subjects: 43
Study: 27764151

Group type: EXPERIMENTAL
Intervention: Mindful breathing condition (n = 12)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal condition (contrast group, n = 12)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-training condition (control group, n = 12)
Number of subjects: 36
Study: 25063879

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal during a socially evaluative speech task (Experiment 1)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal during a physical pain cold pressor task (Experiment 2)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal (Experiment 2)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control condition (both experiments)
Number of subjects: 184
Study: 22150099

Group type: EXPERIMENTAL
Intervention: Female physicians providing care to female patients
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Female patient-female physician dyad
Number of subjects: 509

Group type: COMPARATOR
Intervention: Male patient-male physician dyad
Number of subjects: 509
Study: 18435867

Group type: EXPERIMENTAL
Intervention: Peer counselling scheme
Number of subjects: 0
Study: 22024022

Group type: EXPERIMENTAL
Intervention: Hüttenbrink's method (Group 1)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Author's method (Group 2)
Number of subjects: 125
Study: 15788107

Group type: EXPERIMENTAL
Intervention: 375 ml red wine daily for 2 weeks
Number of subjects: 20
Study: 12477587

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 50
Study: 10512406

Group type: EXPERIMENTAL
Intervention: 8-Fr nasogastric tube
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10-Fr nasogastric tube
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 12-Fr nasogastric tube
Number of subjects: 29

Group type: COMPARATOR
Intervention: Baseline (no nasogastric tube)
Number of subjects: 29
Study: 7557176

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 1835850

Group type: EXPERIMENTAL
Intervention: Hexa‐CAF (hexamethylmelamine, cyclophosphamide, methotrexate, 5‐fluorouracil)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: CHAP‐5 (cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin for 5 days)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Cisplatin (retreatment)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Combination chemotherapy with cisplatin
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Grade 1 tumours (well differentiated)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Other grades of tumours
Number of subjects: 377

Group type: COMPARATOR
Intervention: Microscopic disease at second‐look
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Complete remission
Number of subjects: 377
Study: 7039400

Group type: EXPERIMENTAL
Intervention: Terbutaline depot tablets 7.5 mg twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terbutaline tablets 5 mg three times a day
Number of subjects: 0
Study: 31727415

Group type: EXPERIMENTAL
Intervention: Dienogest 0.5 mg/d
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Dienogest 1 mg/d
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg/d
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 0.02 mg/drospirenone 3 mg (reference drug)
Number of subjects: 235
Study: 29065707

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536 (5×10^9 cfu)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 27419081

Group type: EXPERIMENTAL
Intervention: Ginger powder supplementation (1 g/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (500 mg starch)
Number of subjects: 120
Study: 23824624

Group type: EXPERIMENTAL
Intervention: HPV-positive women
Number of subjects: 96

Group type: COMPARATOR
Intervention: CIN2/3
Number of subjects: 96
Study: 23258609

Group type: EXPERIMENTAL
Intervention: Bright light intervention (2,500 lux for 45-60 min)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 20726255

Group type: EXPERIMENTAL
Intervention: OPV (HDC) vaccine
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control vaccines
Number of subjects: 1200
Study: 18158289

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 2022

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2022
Study: 16171661

Group type: EXPERIMENTAL
Intervention: Hypotensive epidural anesthesia (HEA) with bupivacaine (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hypotensive total intravenous anesthesia (HTIVA) with propofol and remifentanil (n = 20)
Number of subjects: 40
Study: 12606177

Group type: EXPERIMENTAL
Intervention: Buprenorphine (16 mg sublingually for 12 months; supervised daily administration for at least 6 months, possible take-home doses thereafter)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (tapered 6 day regimen of buprenorphine followed by placebo)
Number of subjects: 40
Study: 10531156

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) by pMDI, 1.76 mg (250 microg ex-valve, 220 microg ex-actuator)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) by pMDI with 750-mL spacer
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) by pMDI, 250 microg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo by pMDI
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) by pMDI
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) by pMDI with spacer
Number of subjects: 14
Study: 8759811

Group type: EXPERIMENTAL
Intervention: Monophasic waveforms with reversed polarity
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Biphasic waveforms with reversed polarity
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Monophasic waveforms with reversed polarity in high threshold subgroup
Number of subjects: 26

Group type: COMPARATOR
Intervention: Biphasic waveforms
Number of subjects: 26
Study: 1834093

Group type: EXPERIMENTAL
Intervention: Enalapril (5‐20 mg daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27